Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue

Table 1 Characteristics of participants included in the study

	BPH (n = 6)	OCPCa (n = 6)	EPCa (n = 6)	P
Age (years)	67.4 ± 3.9	59.4 ± 2.9	66.9 ± 2.3	0.140^a
BMI (kg/m²)	26.5 ± 1.5	25.2 ± 1.3	26.5 ± 1.6	0.783^a
Serum total PSA (ng/mL)	8.9 ± 4.7	6.7 ± 1.6	14.7 ± 3.0	0.114^b
Prostate weight (g)	107.0 ± 12.9	40.8 ± 4.2	71.2 ± 9.5	0.001^{a, c}
Serum leptin (mg/mL)	3.7 ± 1.0	7.1 ± 2.5	4.9 ± 1.8	0.453^a
Combined Gleason score
≤7 (3+4), n (%)	---	5 (83%)	4 (67%)	1.000^d
≥7 (4+3), n (%)	---	1 (17%)	2 (33%)

Continuous variables are presented as mean ± SE. ^aANOVA for independent measures; ^bKruskal-Wallis test; ^cLSD post-hoc analysis: BPH versus organ confined PCa, P <0.0001, BPH versus extra prostatic cancer, P = 0.018, extra prostatic cancer versus organ confined PCa, P = 0.040; ^dFisher exact test. Median (interquartile range) values for serum total PSA: BPH, 4.7 (3.7 to 18.4) ng/mL; organ confined cancer, 5.1 (4.1 to 10.2) ng/mL; extra-prostatic cancer, 14.7 (8.3 to 21.2) ng/mL. ANOVA, analysis of variance; BMI, body mass index; BPH, benign prostatic hyperplasia; EPCa, extra prostatic cancer; OCPCa, organ confined prostate cancer; PCa, prostate cancer; PSA, prostate specific antigen.

ISSN: 1741-7015